4-Chloropyrroro[2,3-d]pyrimidine 3680-69-1

Basic Information:
Chinese Name: 4-Chloropyrrolo[2,3-d]pyrimidine
Chinese aliases: 4-chloropyrroloopimidine
6-Chloro-7-azapurine
6-Chloro-7-denazine
4-Chloropyrrole[2,3-d]pyrimidine
4-Chloropyrazole-(2,3-D)pyrimidine
4-Chloro-5 hydropyrrole[3,2-d]pyrimidine
4-Chloro-7H-pyrrole[2,3-d]pyrimidine
4-Chloro-7H-pyrrole[2,3-D]pyrimidine
6-Chloro-7-azapurine (tofacitinib intermediate)
4-Chloro-5H-pyrrolo[3,2-d]pyrimidine
4-Chloro-7-hydropyrrole-[2,3-D]pyrimidine
4-Chloro-5-H-pyrrole[3,2-d]pyrimidine
4-Chloro-7-hydropyrrole-[2,3-d]pyrimidine
4-Chloro-7(H)-pyrrolo[2,3-D]pyrimidine
English name: 4-Chloro-7H-pyrrolo[2,3-d]pyrimidine
Synonyms: 6-Chloro-7-deazapurin
6-Chloro-7-deazapurine
6-CHLORO-7-DEAZAPURINE
4-Chloropyrrolo[2,3-d]pyrimidine
4-CHLOROPYRROLO[2,3-D]PYRIMIDINE
4-methyl-1,3-thiazole-2,5-diamine
4-chloro-7H-pyrollo[2,3d]pyrimidine
4-Chloro-5H-pyrrolo[3,2-d]pyrimidine
4-Chloro-1H-pyrrolo(2,3-d)pyrimidine
4-CHLORO-4H-PYRROLO[2,3-D]PYRIMIDINE
4-CHLORO-7H-PYRROLO[2,3-D]PYRIMIDINE
4-chloro-7H-pyrrolo[2,3-d]pyrimidine
4-Chloro-5H-pyrrol[3,2-d] pyrimidine
4-Chloro-1H-pyrrolo[2,3-d]pyrimidine
4-CHLORO-1H-PYRROLO(2,3-D)PYRIMIDINE
Chloro-5H-pyrrol[3,2-d]pyrimidine, 4-
7H-Pyrrolo[2,3-d]pyrimidine,4-chloro-
4-Chloro-5H-pyrrolo[3,2-D] pyrimidine
5H-Pyrrolo[3,2-d]pyrimidine, 4-Chloro-
CAS registration number: 3680-69-1
84905-80-6
EINECS number: 628-079-2
Molecular formula: C6H4ClN3
Molecular weight: 153.57
 

Physical and chemical properties:
Appearance: white to off-white powder
Melting point: 188-194 °C
Boiling point: 289.2±50.0 °C (Predicted)
Relative density (water = 1): 1.61±0.1 g/cm3 (Predicted)

        
Quality indicators:
Appearance: white to off-white powder
Assay: ≥98%

Additional Information:
Packaging and storage: room temperature, protected from light, ventilated and dry place, sealed and stored
Uses: Intermediates of the API tofacitinib for the treatment of adult patients with moderate to severe rheumatoid arthritis who have insufficient methotrexate response or intolerance; Tofacitinib intermediates.